The article you requested is
Not So Selective Serotonin Reuptake Inhibitors
J Clin Psychiatry 1998;59:333-343
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Selective serotonin reuptake inhibitors (SSRIs) got this name from their greater selectivity (10-fold or more) for blocking serotonin reuptake rather than norepinephrine reuptake. They also lack the sodium channel blocking properties of the tricyclic antidepressants, making them safe in overdose. In addition, SSRIs have less affinity for α1-receptors, muscarinic cholinergic receptors, and histamine-1 receptors compared with the tricyclic antidepressants, leading to the greater tolerability profile of SSRIs.